Madrigal Pharmaceuticals ... (MDGL)
NASDAQ: MDGL
· Real-Time Price · USD
326.72
-7.19 (-2.15%)
At close: May 01, 2025, 3:59 PM
328.51
0.55%
Pre-market: May 02, 2025, 04:29 AM EDT
Company Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases.
Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis.
The company also develops MGL-3745, a backup compound to resmetirom.
It has research, development, and commercialization agreement with Hoffmann-La Roche.
Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Feb 6, 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 528 |
| CEO | William J. Sibold |
Contact Details
Address: Four Tower Bridge West Conshohocken, Pennsylvania United States | |
| Website | https://www.madrigalpharma.com |
Stock Details
| Ticker Symbol | MDGL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001157601 |
| CUSIP Number | 558868105 |
| ISIN Number | US5588681057 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| William J. Sibold | Chief Executive Officer, President & Director |
| Ronald Filippo | Chief Information Officer |
| Clint Wallace | Chief Human Resources Officer |
| Dr. Rebecca A. Taub M.D. | Founder, Senior Scientific & Medical Advisor and Director |
| Dr. Robert E. Waltermire Ph.D. | Chief Pharmaceutical Development Officer |
| Dr. Stephen Dodge M.B.A., Pharm.D. | Senior Vice President of Global Medical Affairs |
| Edward Chiang | Senior Vice President of Clinical & Technical Operations |
| Mark Underwood | Senior Vice President of Business Planning & Operations |
| Thomas W. Hare | Senior Vice President of Clinical Management |
| Tina E. Ventura | Chief Investor Relations Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 01, 2025 | 10-Q | Quarterly Report |
| May 01, 2025 | 8-K | Current Report |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Filing |
| Apr 29, 2025 | DEF 14A | Filing |
| Apr 24, 2025 | 3 | Filing |
| Apr 17, 2025 | 8-K | Current Report |
| Mar 14, 2025 | 4 | Filing |
| Mar 12, 2025 | 4 | Filing |
| Mar 12, 2025 | 4 | Filing |